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Obesity is associated with the accumulation of pro-inflammatory cells in visceral adipose
tissue (VAT), which is an important underlying cause of insulin resistance and progres-
sion to diabetes mellitus type 2 (DM2). Although the role of pro-inflammatory cytokines
in disease development is established, the initiating events leading to immune cell acti-
vation remain elusive. Lean adipose tissue is predominantly populated with regulatory
cells, such as eosinophils and type 2 innate lymphocytes. These cells maintain tissue
homeostasis through the excretion of type 2 cytokines, such as IL-4, IL-5, and IL-13,
which keep adipose tissue macrophages (ATMs) in an anti-inflammatory, M2-like state.
Diet-induced obesity is associated with the loss of tissue homeostasis and development
of type 1 inflammatory responses in VAT, characterized by IFN-γ. A key event is a shift
of ATMs toward an M1 phenotype. Recent studies show that obesity-induced adipocyte
hypertrophy results in upregulated surface expression of stress markers. Adipose stress
is detected by local sentinels, such as NK cells and CD8+ T cells, which produce IFN-γ,
driving M1 ATM polarization. A rapid accumulation of pro-inflammatory cells in VAT
follows, leading to inflammation. In this review, we provide an overview of events lead-
ing to adipose tissue inflammation, with a special focus on adipose homeostasis and the
obesity-induced loss of homeostasis which marks the initiation of VAT inflammation.
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Introduction
Over the past few decades, we have seen a dramatic worldwide
increase in the incidence of obesity and its associated patholo-
gies, such as insulin resistance, which contributes to the develop-
ment of metabolic syndrome and diabetes mellitus type 2 (DM2)
[1]. Metabolic syndrome is a cluster of conditions such as ele-
vated blood glucose, elevated blood pressure, excess body fat, and
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abnormal lipid (cholesterol) levels, which together increase the
risk of diabetes mellitus and cardiovascular disease. DM2 is char-
acterized by high blood glucose levels, which is a direct result of
reduced systemic sensitivity to the anabolic hormone insulin. An
important underlying cause of obesity-induced insulin resistance is
chronic low-grade systemic inflammation (reviewed in [2]). The
long-term presence of pro-inflammatory cytokines in the blood
blunts the signal transduction capacity of the insulin receptor in
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insulin-sensitive tissues [3]. Obesity-induced systemic inflamma-
tion is thought to originate predominantly in adipose tissue. The
human body contains various types of fat depots, generally divided
in white and brown fat. The role of brown adipose tissue is to pro-
duce body heat and in humans is mostly found in newborns, even
though adults do have small amounts of this type of fat [4]. The
role of white adipose tissue (WAT) is to store nutrients in the form
of a single large fat droplet. In addition, WAT is an important sen-
sor of the metabolic state of an organism and is therefore one of
the main endocrine organs in the body [5]. WAT can be found
at multiple sites in the body and can be further subdivided based
on location and on differences in precursor cells that give rise
to these organs [6]. For example, retroperitoneal WAT is derived
from a precursor that requires expression of the transcription fac-
tors Myf5 and Pax3, whereas these genes are not essential for the
development of mesenteric WAT. In contrast, male perigonadal
WAT does not require Myf5, but is partially dependent on Pax3
for its development in mice [6].
Of these various fat tissues, the intra-abdominal fat depots,
collectively referred to as visceral adipose tissue (VAT), have been
shown to be the predominant source of chronic systemic inflamma-
tion and most important for the development of DM2 [2]. When
the perigonadal fat pads of mice were surgically removed 2 weeks
before initiation of HFD feeding, a significant reduction of glucose
intolerance and insulin resistance was observed in mouse models
of obesity-induced DM2 [7]. VAT contains a relatively large popu-
lation of immune cells, which changes dramatically in its composi-
tion during the development of obesity [2]. Recently, various stud-
ies have provided further insight in the earliest changes that occur
within the immune cell composition of VAT in response to diet-
induced obesity (DIO). In this review, we provide a brief overview
of the events that ultimately results in adipose tissue inflamma-
tion and systemic insulin resistance. We focus on the initial stages
of immune cell activation, which represent the equivalent of the
astronomical ‘Big Bang’ for adipose tissue inflammation. Whereas
many of these events will (partially) overlap, we present them as
consecutive events to facilitate understanding.
Adipose tissue in homeostasis
The immune system plays an important role in the control of
adipose tissue structure and homeostasis. Two main functions of
the immune system in fat can be distinguished: (i) inhibition of
tissue inflammation and (ii) tissue (re)modeling. Much attention
has been given to regulation of immune cell activation in VAT,
since loss of immune cell inhibitory mechanisms drives the tissue
inflammation that contributes to insulin resistance. However,
various immunological deficiencies (described below) result
either in reduced or increased adipose tissue mass, with obvious
implications for the endocrine function of fat. Therefore, a
better understanding of tissue remodeling by the immune system
may have important implications for the current pandemic of
obesity.
Figure 1. Control of adipose tissue homeostasis under lean conditions.
Healthy adipose tissue is populated by a type 2-polarized immune sys-
tem, which maintains ATMs in an M2-like state. Dominant immune
cell subsets under these conditions are eosinophils, iNKT cells, and
Treg cells, which produce IL-4, IL-13, and IL-10, respectively. Adipocytes
also contribute to the type 2 immune response through the produc-
tion of adiponectin. ILC2s regulate eosinophil numbers through the
production of IL-5. Type 2 immune cells are supported by a stromal
structure which promotes immune cell viability through the produc-
tion of several cytokines, most importantly IL-33. In addition to sus-
taining a type 2 immune cell environment, adipose tissue cells engage
in extensive cross-talk to (re)model adipose tissue structure and phe-
notype. One example is the formation of ‘brown in white’ adipocytes
from adipocyte precursors ‘beiging’ through the production of IL-4, IL-
13, and Met-Enkephalin by the ILC2/eosinophil axis. NKT: Invariant-
Chain Natural Killer T cell; TReg: regulatory T cell; Eo: Eosinophil; M2: M2
Macrophage; ILC2: Innate Lymphocyte 2; AP: adipocyte precursor; Brite:
‘Brown in white’ adipocyte; Stroma: adipose tissue stroma; MetEnk:
Met-enkephalin.
Inhibition of immune cell activation
in adipose tissue
Under lean conditions, adipose tissue is populated by a number
of immune cells (Fig. 1). These cells either inhibit immune cell
activation or promote a Th2-type response, characterized by
the production of cytokines such as IL-4, IL-5, and IL-13 [8]. In
lean tissue, macrophages have been shown to be a dominant
immune cell population, and the majority of these cells have
an M2-like (or alternatively activated) phenotype (Fig. 1) [9].
Lean adipose tissue macrophages (ATMs) express arginase-1,
which inhibits iNOS activity, and produce anti-inflammatory
molecules, such as IL-10 and IL-1Ra [9]. Importantly, under
nonobese conditions, macrophages have been shown to play
a key role in inhibiting immune cell activation in murine fat.
In mouse models where ATMs fail to respond to M2-polarizing
stimuli, an increase of pro-inflammatory cytokines, such as TNF
and IL-1β, has been observed. [10, 11]. The M2 phenotype of
ATMs is maintained by a number of immune cells, as well as by
adipocytes. IL-4 has been shown to be an important cytokine that
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drives M2 polarization [10]. In adipose tissue, eosinophils are the
dominant source of IL-4. Deficiency of these cells in dblGATA
mice, or hyper-eosinophilia in IL-5 transgenic animals, has been
shown to result in reduced or increased numbers of M2-like
macrophages, respectively [11]. VAT-resident eosinophils depend
on IL-5 for their survival, which is mainly produced by type 2
innate lymphoid cells (ILC2s) in this organ [12]. Elimination of
any component of the ILC2/eosinophil/M2-ATM axis has been
shown to result in an increase in pro-inflammatory cytokines in
VAT and increased sensitivity to obesity-induced development of
insulin resistance, making this particular axis one of the dominant
regulatory mechanisms of adipose tissue homeostasis [11–13].
Invariant-chain natural killer T (iNKT) cells represent a sec-
ond immune cell population which sustains M2 ATMs in VAT
(Fig. 1). These cells are present at relatively high frequency in
lean fat and recognize lipid antigens in the context of CD1d [14].
Lack of iNKT cells as a result of Vα18 or CD1d deficiency in mice
leads to reduced adipose tissue levels of IL-4 and IL-13, as well as
to increased pro-inflammatory ATM numbers (reviewed in [15]).
The role of iNKT cells may change in response to obesity, as it
has been reported that these cells can also promote insulin resis-
tance following DIO [15]. The exact mechanism via which iNKT
cells inhibit adipose tissue inflammation under homeostasis, yet
promote it in models of DIO, has yet to be resolved.
Regulatory T (Treg) cells represent a second T-cell subset that
is directly involved in the inhibition of adipose tissue inflamma-
tion. CD4+ T cells are the most predominant T cells in adipose
tissue and compared to other tissues, a very large fraction of these
is Foxp3-positive, which was shown to depend on the cytokine
IL-33 [16] and the nuclear receptor PPAR-γ [17]. Regulatory T
cells in VAT repress immune cell activation through production
of the anti-inflammatory cytokine IL-10 [18]. Experimental abla-
tion of Treg cells by injection of diphtheria toxin in mice express-
ing the diphtheria toxin receptor under the Foxp3 promoter was
shown to result in an increase of pro-inflammatory cytokines such
as TNF, IL-6, and RANTES in fat [18]. Importantly, elimination
of Treg cells acutely reduced insulin sensitivity in these animals
[18], whereas transfer of Treg cells into T-cell-deficient animals
improved insulin sensitivity upon DIO [19].
In addition to immune cells, adipocytes and adipose stroma
contribute to tissue homeostasis. Adipose tissue excretes a num-
ber of factors, generally referred to as adipokines, which play
an important role in the regulation of systemic metabolism [20].
Many of these factors share homologies with cytokines and have
profound impact on immune cell behavior. One of the most well-
characterized adipokines is adiponectin (Fig. 1). This molecule
shares functional homology with insulin, and has been shown to
impair gluconeogenesis in the liver and promote glucose uptake
[21]. In addition, adiponectin has a strong anti-inflammatory
effect [22]. In vitro stimulation assays showed that the adiponectin
receptor is expressed at relatively high levels on M2 macrophages,
whereas M1 polarization results in its downregulation, explain-
ing the stronger effect of adiponectin on the former ATM subset
[22]. Adiponectin inhibits NF-κB activation and promotes IL-10
and IL-1Ra production by macrophages. Moreover, adiponectin
suppresses TLR4 signaling [22], which has been shown to be
important for diet-induced insulin resistance [23].
Immunological control of adipose tissue
structure
Various immune cell subsets have been implicated in the con-
trol of adipose tissue remodeling. KitW-sh mice, which lack mature
mast cells, have been shown to have strikingly less adipose tissue
mass than wild-type animals [24]. In addition, KitW-sh mice show
reduced adipose tissue expansion upon feeding with a high-fat
diet, when compared with that in wild-type controls [24]. Mast
cells were shown to promote microvessel growth by excreting IL-6
and IFN-γ, which appear to be essential for healthy adipose tissue
formation and expansion [24]. In contrast, mice deficient for IL-17
demonstrated increased adipose tissue mass gain in response to
HFD [25]. A normal, low-fat diet did not result in altered adipose
tissue mass in these animals, suggesting that adipogenesis induced
by the abundant presence of nutrients differs from basic ontogene-
sis of adipose organs. Immune cell derived stimuli are also capable
of inhibiting adipogenesis. IL-5 transgenic animals, which suffer
from eosinophilia, have been shown to have reduced adipose tis-
sue mass, whereas dblGATA mice, which lack eosinophils, have
larger fat pads than wild-type animals, both under lean and obese
conditions [11]. Deletion of iNKT cells, as a result of genetic defi-
ciency for CD1d or Jα18, results in an increase of adipose tissue
mass only after high-fat feeding [26, 27]. The mechanisms via
which these cells control white adipose tissue proliferation are
currently unclear.
A cytokine of particular interest for adipose tissue homeostasis,
because it affects both immune cell behavior and adipose tissue
remodeling, is IL-33 [28]. IL-33 is a member of the IL-1 superfam-
ily and binds to the receptor ST2, which is highly expressed on
mast cells, Th2 CD4+ T cells, and ILC2s [29]. Under homeostatic
conditions IL-33 is mainly expressed by epithelial cells and tissue
stroma [30]. Upon infection, IL-33 expression is highly induced
in many tissues and it was therefore originally classified as a
pro-inflammatory mediator which drives anti-helminth immune
responses [29]. Under noninflammatory conditions, IL-33 sus-
tains type 2 immune cells, including ILC2s and M2 macrophages,
in order to maintain tissue homeostasis (reviewed in [29]). In
VAT, IL-33 is abundantly expressed in adipose tissue stroma, pre-
dominantly by endothelial cells and fibroblast-like reticular cells
[29, 30]. Adipose tissue Treg cells express high levels of ST2 and
deficiency of this receptor results in a specific loss of Treg cells
in fat, but not in other organs [16]. IL-33 also plays a role in the
maintenance of adipose tissue eosinophils, as blocking of ST2 was
shown to result in a significant reduction in the number of these
cells, independently of ILC2s [31].
Of particular interest is the effect of IL-33 on ILC2s. Exogenous
administration of IL-33 increases the number of ILC2s in VAT,
with a concomitant increase of IL-5 levels and eosinophil cell
numbers [12]. Strikingly, in response to IL-33, ILC2s regulate
adipocyte phenotype and function. For example, IL-33 deficiency
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results in increased body mass and increased formation of glucose
intolerance in response to high-fat feeding, due to a lack of
Type 2 ILCs [16, 32]. Moreover, ‘Brite’ (Brown in white) cell
numbers, which are UCP1-expressing adipocytes in white fat with
a brown adipocyte phenotype, were shown to be decreased in
these animals [32, 33]. Two recent studies have shown that IL-33
activates ILC2s to produce IL-13 and the endogenous opioid Met-
enkephalin, which drives adipocyte precursors to differentiate
into Brite cells, a process also known as ‘beiging’ [32, 33]. Future
studies are required to show whether other cells that produce
IL-13 in fat, such as iNKT cells, are also capable of skewing pre-
adipocyte differentiation. Nevertheless, since the role of IL-33 in
beiging is most prominent in subcutaneous fat, it comprises most
likely a different biological mechanism than its anti-diabetic and
anti-adipogenic effects on VAT. In addition, the biological signif-
icance of beiging requires further study, as it is currently unclear
whether it protects against development of insulin resistance
following DIO.
Reaching critical mass: obesity-driven
immune cell accumulation in VAT
The early phases of DIO in visceral adipose fat are characterized by
an increase in the amount of fat per adipocyte and by an accumu-
lation of immune cells which initially are of limited inflammatory
capacity. The most commonly used animal model for the induc-
tion of obesity and obesity-induced insulin resistance is by feeding
animals, usually mice, with a high-fat diet (HFD). Within the first
weeks after start of HFD feeding, mice accumulate neutrophils,
macrophages, and NK cells in VAT. Data showing the biological
relevance of these cells in VAT will be discussed below.
Neutrophils
Already in the first days after initiation of HFD feeding in mice,
neutrophil numbers rapidly increase in adipose tissue and produce
the proteolytic enzyme elastase [34]. Even after long term (>3
months) HFD feeding, however, neutrophils remain a minor frac-
tion of adipose tissue leukocytes. Nevertheless, elastase deficiency
or chemical inhibition of elastase was shown to result in enhanced
insulin sensitivity compared to wild-type mice upon 12 weeks
of HFD feeding. In vivo administration of exogenous elastase
resulted in acute reduction of insulin sensitivity in hepatocytes
[34]. These experiments demonstrate the importance of elastase
in metabolic disease, even though it is currently unclear how this
enzyme contributes to adipose tissue inflammation. The immedi-
ate trigger for neutrophil infiltration into the VAT following DIO
is also unknown. It has been shown in humans that acute lipid
overload induces an inflammatory boost, as demonstrated by an
increase of circulating MCP1 and C-reactive protein [35]. Alter-
natively, HFD is thought to induce acute changes in the adipose
tissue microenvironment, such as alterations in oxygen consump-
tion, following a brief surge in adipocyte precursor proliferation
[36]. This acute stress may be involved in recruiting neutrophils
to this site in the first days following initiation of high-fat
feeding.
Macrophages and NK cells
Compared with that of neutrophils, the increase in the numbers of
adipose tissue macrophages and NK cells appears to be delayed,
occurring in weeks, rather than days after the start of HFD
feeding. Although neutrophils in VAT are thought to be primarily
of peripheral origin [34], ATMs and NK cells appear to increase
partially or completely through proliferation of tissue-resident
populations [7, 37, 38]. When mice fed an HFD were intra-
venously injected with labeled NK cells, tracing of the labeled
cells demonstrated that only a small number of NK cells reach the
adipose tissues from the periphery. In contrast, BrdU labeling, as
a marker of proliferation, was significantly increased in adipose-
tissue resident NK cells, but not in splenic NK cells following HFD
[7]. This suggests that the increase in NK cells in VAT is due to
proliferation of the tissue-resident population rather than influx
from the periphery. The origin of increased macrophage popula-
tions in the VAT in response to HFD appears to be more complex.
One study demonstrates that local proliferation of these cells is the
dominant source of cellular increase [38]. Other studies, in which
the capacity of macrophages to respond to chemo-attractants was
blocked, showed reduced macrophage cell numbers in VAT due
to decreased peripheral influx [37, 39]. Possibly, both depots
contribute to the ATM pool in the case of chronic inflammation
in VAT.
Regulatory cells: ILC2s, Treg cells, and
eosinophils
In addition to the accumulation of pro-inflammatory cells in
VAT, DIO is also associated with a decrease in anti-inflammatory
immune cells. In humans and mice, ILC2s were shown to be
reduced in adipose tissue of obese individuals, both relative to
the total number of leukocytes and per gram of adipose tissue
[32]. This decrease appears to involve the inhibition of ILC2s to
respond to IL-33 in the presence of the type 1 cytokine IFN-γ [40].
Similarly, Treg cells decrease in number per gram of fat following
DIO, and especially relative to the number of effector CD8+ and
CD4+ T cells. The relative inhibitory capacity of this cell popula-
tion therefore decreases in response to DIO, which was shown to
be an important contributor to VAT inflammation [16, 18, 19].
Finally, eosinophils also decrease in number following DIO, possi-
bly as a result of the decreased numbers of ILC2s, which produce
the IL-5 required for the maintenance of this population [11, 12].
Thus, the regulatory capacity of inhibitory immune cell subsets
in VAT decreases due to a relative decrease in the contribution
of these cells per gram of fat and as a percentage of the overall
immune cell pool.
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Adipose tissue
The crucial trigger for the increase of immune cells in adipose
tissue in response to DIO is still unclear, but is likely to be derived
from adipocytes. Via lineage tracing of adipocyte precursors, it
was shown that the increase in adipose tissue mass early after
HFD feeding is predominantly the result of adipocyte hypertrophy
[36, 41]. Despite an early surge in pre-adipocyte proliferation,
only prolonged exposure to HFD (> 4 weeks) increases mature
adipocyte cell numbers (hyperplasia) [36, 41]. With the increase
of adipose tissue mass, several changes occur in adipokine produc-
tion. Most notably, adiponectin production drops, which results in
decreased glucose uptake and reduced anti-inflammatory regu-
lation of the local tissue environment [22]. Instead, adipocytes
start producing more leptin. Leptin affects the hypothalamus,
where it triggers satiety signals, thereby directly inhibiting the
effects of ghrelin, a hormone produced in the gut that stimulates
hunger [22]. Leptin levels in the blood closely correlate with the
amount of adipose tissue mass, both in humans and mice [42].
In addition to its central effects, leptin has a profound effect on
the immune system. The leptin receptor, also known as LEP-R or
CD295, is expressed on most immune cells including neutrophils,
macrophages, andNK cells. LEP-R shares structural homologywith
the IL-6 receptor and also signals through Stat3 [43]. Mice that are
deficient for leptin (ob/ob) or for LEP-R (db/db) are obese due to
increased food intake as a result of never feeling sated. In addition,
they have a strong reduction in functional immune cells, such as
(regulatory) T cells [44], NK cells, and dendritic cells (reviewed
in [45]). Importantly, T cells and B cells have been shown to
increase expression of LEP-R in response to activation [46]. More-
over, survival of activated lymphocytes was enhanced when leptin
was added to the cell culture [46]. Increased leptin production by
adipose tissue may be an important initial trigger for immune cell
increase in VAT in response to obesity. Indeed, in the first weeks
after start of HFD feeding, macrophage and NK-cell numbers and
functionality are specifically increased in VAT, whereas they are
reduced in ob/ob mice [7, 47]. Moreover, leptin has been shown
to promote NK-cell survival in the bone marrow [48] and intra-
venous administration of leptin resulted in a specific increase of
granulocytes, monocytes, and NK cells in the circulation of rats
[49].
In addition to leptin, adipose tissue produces other adipokines
that affect immune cell numbers in VAT, most notably monocyte
chemo-attractant protein-1 (MCP-1) and IL-6 (Fig. 2). MCP-1 is
a potent chemokine that recruits monocytes and its levels are
increased in the serum of DM2 patients [50]. Mice deficient for
MCP-1 have a significant reduction in adipose tissue inflamma-
tion and a delayed onset of insulin resistance in response to DIO
[37]. The role of IL-6 in obesity appears to be more complex
and shares parallels with IL-33; IL-6 is generally assumed to be a
pro-inflammatory mediator and its levels have been shown to be
significantly increased in obese individuals [51]. The IL-6 receptor
comprises the gp130 and IL-6R subunits. Although IL-6 can bind
directly to this receptor complex, IL-6 can also be bound to a solu-
ble form of gp130 and be transpresented to cells that express only
the IL-6R subunit [52]. Transpresentation of IL-6 bound to gp130
has been shown to be crucial for the accumulation of macrophages
in adipose tissue [53]. Paradoxically, IL-6-deficient mice develop
late-onset glucose tolerance [54]. IL-6 has been shown to stimulate
IL-4R expression on macrophages, thereby promoting M2 polar-
ization of these cells [10], and macrophages express high levels
of the IL-6 receptor. Therefore, similarly to IL-33, under homeo-
static conditions IL-6 appears to function as an anti-inflammatory
mediator by preventing M1 macrophage formation. In response to
DIO, IL-6 levels increase [55], allowing other, pro-inflammatory
cells to be activated by this cytokine. Therefore, the effects of IL-6
on the development of DM2 appear to be time- and concentration
dependent.
In addition to the factors mentioned above, there is an increas-
ingly large number of adipokines that has been shown to mediate
immune cell function in adipose tissue, such as resistin, visfatin,
and apelin [56]. The exact role of these molecules in the promo-
tion or inhibition of obesity-induced VAT inflammation and the
development of insulin resistance is mostly unclear. However, the
sheer number of immune-modulatory molecules derived from adi-
pose tissue clearly illustrates the extensive communication of fat
with its tissue-resident immune system.
The “Big Bang”: Initiation of inflammation
in VAT
Whereas the accumulation of immune cells predisposes an organ
to tissue inflammation, in itself this local accumulation is insuf-
ficient for the activation of the immune system. A key event in
the induction of obesity-induced VAT inflammation and devel-
opment of insulin resistance appears to be the polarization of
macrophages from an M2 to a pro-inflammatory M1-like state
[9, 13]. In evidence of this, depletion of M1 macrophages in both
humans and mice has been shown to cause significant improve-
ment of systemic insulin resistance [13, 57]. Pro-inflammatory
licensing of macrophages is therefore crucial for the development
of VAT inflammation, as they appear to be the primary source
of pro-inflammatory cytokines that are found in the circulation
of subjects with diabetes [55]. In addition, macrophages potently
recruit T cells via the production of chemokines such as CXCL16
[58], a molecule of which the expression is greatly increased in
adipose tissue in response to obesity [59]. Thus, macrophages
contribute both directly and indirectly to the excretion of pro-
inflammatory cytokines.
Systemic sources of immune activation
Various stimuli for M1 macrophage priming have been pro-
posed, including free fatty acids (FFAs) and microbial components
[23, 60]. FFAs are normal components of our food, but they are
also the vehicle by which triacylglycerol stored in adipose tissue
is transported through the bloodstream [61]. FFAs are used as
a source of fuel by many tissues, including skeletal muscle and
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Figure 2. Model for development of obesity-induced adipose tissue inflammation. In response to HFD, adipocytes initially become hypertrophic
and later hyperplastic (indicated by increase in size and number of adipocytes, respectively). This is associated with a shift in adipokine production
from adiponectin to leptin/MCP-1 and an increase in the number of ATMs, neutrophils, and NK cells in visceral fat. As obesity persists, adipocyte
stress drives CD8+ T-cell and NK-cell activation through NKp46, resulting in local production of IFN-γ. Together with PAMPs coming from
the periphery, this locally produced IFN-γ licenses ATMs toward a pro-inflammatory M1 state. This makes these cells sensitive to a range of
pro-inflammatory stimuli, such as leukotrienes, FFA-Fetuin-A complexes, and DAMPs from necrotic adipocytes. As a result, ATMs produce pro-
inflammatory cytokines, such as TNF and IL-1β, and recruit more pro-inflammatory cells, including CD4+ T cells, CD8+ T cells, and B cells, into
the VAT to amplify the immune response. The chronic systemic presence of pro-inflammatory cytokines derived from this response ultimately
contributes to the development of insulin resistance. M1: M1 Macrophage; M2: M2 Macrophage; N: Neutrophil; NK: natural killer cell; IFN-γ:
interferon gamma; PAMP: pathogen-associated molecular pattern; FFA: free fatty acid; DAMP: danger-associated molecular pattern; TNF: tumor
necrosis factor.
the brain [61]. Uncontrolled (i.e., nontreated) diabetes patients
have increased amounts of FFAs in circulation [62]. Importantly,
FFAs were shown to be able to stimulate TLR4 on macrophages,
but only when bound to the protein carrier Fetuin-A [23, 63].
Palmitate, an FFA found in many food sources, including palm
oil, cheese, and meat, has been shown to drive activation of the
inflammasome, the protein complex responsible for the formation
of pro-inflammatory cytokines IL-1β and IL-18 [64]. Recently, the
role of FFAs as initiators of inflammation is being questioned.
In large cohort studies of obese nondiabetic individuals, the lev-
els of FFAs in the serum did not correlate with BMI [65, 66].
Importantly, meta-analysis shows that serum FFA levels are not
predictive for the formation of DM2 [61]. FFA uptake from the
circulation is controlled by insulin and the increase of FFA levels
in the blood of uncontrolled DM2 patients is therefore thought to
be a result of insulin resistance rather than its cause [61]. Indeed,
well-controlled DM2 patients do not have higher serum levels
of FFA than healthy subjects [61, 67]. Notably, in vitro studies
demonstrate that FFAs can only induce pro-inflammatory cytokine
excretion in macrophages when they are first primed with LPS or
IFN-γ [64]. Thus, before a free fatty acid can function as a pro-
inflammatory mediator, polarization of ATMs is first required. This
observation in turn triggered the hypothesis that obesity-induced
gut dysbiosis drives adipose tissue inflammation, through the leak-
age of microbial components (or pathogen-associated molecular
patterns (PAMPs)) into the blood stream (Fig. 2). Although large-
scale, metagenome-wide association studies on microbial gut DNA
revealed only mild dysbiosis in the intestines of DM2 patients [68],
several micro-organisms could indeed be associated with mark-
ers of metabolic syndrome [69]. Animal studies indicate that an
HFD increases endotoxin levels in the circulation [60, 70]. How-
ever, this could only be achieved when food with a very high fat
content was used, whereas more commonly used high-fat diets
failed to do so [60]. Nevertheless, studies in humans indicate
that HFDs acutely increase systemic endotoxin levels [71]. More
importantly, a large prospective cohort study showed that systemic
endotoxin levels are a risk factor for the development of DM2 [72].
Thus, there is clear evidence that systemic factors, especially diet-
induced endotoxemia, play a role in the development of insulin
resistance. Whether and how these factors affect chronic systemic
inflammation has yet to be elucidated.
Local sources of VAT inflammation
Systemic endotoxemia does not explain, however, why VAT
macrophages specifically would be primed toward an M1 phe-
notype. Rather, a local trigger is required to initiate macrophage
polarization in particularly this tissue. IFN-γ is a potent inducer
of M1 polarization [73]. Mice deficient for this cytokine have
reduced M1 macrophage accumulation in the VAT and improved
insulin sensitivity in response to HFD feeding [74–76]. Therefore,
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obesity-induced IFN-γ production has been suggested to be an
important initiating event in VAT inflammation.
NK cells are the body’s sentinels and browse tissues looking for
signs of cellular stress, activating the immune system in response
to viral infection or oncogenic transformation. NK cells are armed
with a broad repertoire of activating and inhibitory receptors that
recognize self-ligands on target cells. In the absence of inhibitory
ligands (‘missing self’) and/or in the presence of activating lig-
ands (‘induced self’), NK cells are triggered to induce a cytolytic
response, or produce cytokines such as IFN-γ [77]. In several mod-
els, NK cells have been shown to drive M1 macrophage polariza-
tion through the production of IFN-γ [73, 78].
Hypertrophy is a well-known stress factor for adipocytes, lead-
ing to micro-hypoxia, ER stress, and extracellular matrix confine-
ment [79, 80]. Indeed, we have observed that in response to HFD
feeding, murine adipocytes of the visceral fat induce expression of
stress ligands which bind to the activating NK-cell receptor NKp46
(NCR1 in mice) (Fig. 2) [7]. Early after initiation of HFD feeding,
the number of IFN-γ-producing cells increases, and in particular
the number of NK cells [7]. Antibody-mediated depletion of NK
cells or deficiency of NCR1 in mice was shown to result in a signifi-
cant reduction of M1-polarized ATMs upon HFD feeding, whereas
the total number of ATMswas not greatly affected [7, 81]. Further-
more, the development of diet-induced insulin resistance could be
delayed by preventing NK-cell activation using soluble NCR1 [7].
These findings are in line with several recent studies in humans
and mice. VAT from obese humans shows a significant increase in
the number of NK cells compared with that in subcutaneous fat,
and these cells produce higher levels of IFN-γ [76]. In addition,
human adipocytes can stimulate NK cells to produce IFN-γ in vitro
[82].
In addition to NK cells, T cells are an important source of IFN-
γ in VAT [7, 19]. Both CD4+ and CD8+ T-cell numbers strongly
increase in response to DIO and ultimately become themost preva-
lent lymphocytes in VAT, albeit with delayed kinetics compared
to NK cells [7, 83]. In the first weeks after DIO, CD4+ T cells
retain a TH2 phenotype and contribute to the inhibition of VAT
inflammation [19]. CD8+ T cells on the other hand, have been
shown to recruit macrophages through the production of MCP-
1 and their deletion in mice results in a significant decrease in
systemic inflammation and insulin resistance upon DIO [84]. It
is currently unclear whether CD4+ and CD8+ T cells are acti-
vated in VAT through engagement of their T-cell receptor (TCR),
or whether they are recruited in a chemokine-dependent fashion,
independent of TCR engagement. Obese, but not lean adipose tis-
sue was shown to be able to induce proliferation of CD8+ T cells
in vitro [84]. However, whether this is also the way via which
CD8+ T-cell numbers increase in obese VAT in vivo remains to be
investigated.
Finally, NKT cells can be a source of IFN-γ in VAT. Whereas
iNKT cells initially have an anti-inflammatory role in VAT through
the production of IL-4 and IL-13, in response to HFD the number
of TNF and IFN-γ-producing NKT cells strongly increases [7, 83].
Whether and how these cells contribute to initiation of VAT inflam-
mation is still a matter of debate, especially since people using the
samemouse models deficient for iNKT cells found opposing effects
on the development of insulin resistance following DIO [14, 83].
In summary, the increase in macrophage cell numbers in VAT
in response to HFD feeding is promoted by various factors, both
derived from local and systemic sources. However, in order to
achieve their full pro-inflammatory potential, licensing of ATMs by
NK cells and CD8+ T cells through immune cell derived cytokines
such as IFN-γ is required (Fig. 2). The observation that IFN-γ defi-
cient mice still develop insulin resistance in response to HFD feed-
ing, though delayed compared to wild-type animals, also indicates
that this cytokine is not the only factor that drives VAT inflamma-
tion [75].
An additional layer of complexity has recently been added with
the surprising observation that recruitment of pro-inflammatory
macrophages in VAT is not absolutely required for the devel-
opment of obesity-induced insulin resistance. Mice in which IL-
6 trans signaling was impaired showed reduced recruitment of
macrophages into the VAT, but still developed glucose intolerance
[53]. Possibly, redundancy between pro-inflammatory mediators
ensures recruitment of pro-inflammatory cells to the VAT even in
the absence of macrophages.
Inflation of inflammation in the VAT
The later stages of adipose tissue inflammation are well stud-
ied and have been elaborately described in excellent reviews
[2, 15, 85]. Therefore, wewill describe this phase only briefly here.
Priming of macrophages in adipose tissue makes them suscepti-
ble to a range of pro-inflammatory stimuli that are associated with
obesity, described below. In response to obesity, adipocytes induce
expression of enzymes that convert arachidonic acid into pro-
inflammatory mediators, including leukotrienes [39, 86]. Defi-
ciency in key components of leukotriene biology has been shown
to prevent cytokine secretion bymacrophages and obesity-induced
insulin resistance [39, 86]. In addition, obesity has been shown
to induce necrotic cell death of adipocytes as a result of micro-
hypoxia [79]. Necrosis results in the release of danger-associated
molecular patterns (DAMPs), such as double-stranded DNA and
heat shock proteins, which drives macrophages to produce pro-
inflammatory cytokines [87]. Advanced obesity is therefore char-
acterized by adipocytes in VAT that are surrounded by a ring of
pro-inflammatory macrophages, known as crown-like structures
[88]. In addition, priming makes murine macrophages susceptible
to activation by FFAs [63]. These pro-inflammatory stimuli drive
the activation of the JNK and NF-κB signaling cascades and of the
inflammasome in macrophages [87, 89, 90]. The inflammasome
is a protein complex, which converts pro-IL-1 and pro-IL-18 into
IL-1β and IL-18, both potent activators of the immune system [91].
Either genetic deficiency or chemical inhibition for components of
the JNK, NF-κB, or inflammasome pathways has been shown to
strongly reduce obesity-induced insulin resistance in humans and
mice [87, 89, 90].
The activation of macrophages in VAT and the generation of an
inflammatory environment in this tissue subsequently drives the
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recruitment of a plethora of pro-inflammatory cells, mostly with a
TH1 signature. TH1 effector CD4 T cells, CD8 T cells, and B cells
most strongly increase during the later stages of adipose tissue
inflammation [2, 15, 19, 85]. Not only are these cells important
sources of IFN-γ that further drive ATM polarization, they also
contribute to chronic systemic inflammation by producing pro-
inflammatory cytokines such as TNF (Fig. 2). Ultimately, it is the
chronic leakage of these pro-inflammatory cytokines into the blood
stream that forms a strong risk factor for the development of sys-
temic insulin resistance by dampening the signaling capacity of
the insulin receptor in local tissues [3].
Conclusions
Although the immunological complexity of VAT inflammation is
becoming increasingly clear, many questions remain unanswered.
Subcutaneous adipose tissue is comparable in many aspects to its
visceral counterpart, including the capacity to produce leptin and
adiponectin [92], yet it accumulates much less pro-inflammatory
macrophages in response to DIO [93]. Adipose tissue stroma is an
important source of adipokines and has been shown to activate
CD8+ T cells in HFD-fed animals [84, 92]. Therefore, differences
between the connective tissues that support visceral and subcu-
taneous adipocytes are likely to be important. In addition, the
chronic systemic presence of pro-inflammatory mediators cannot
in itself explain the development of insulin resistance. Although
some inflammatory diseases, such as psoriasis, ulcerative colitis,
and systemic vasculitis are associated with an increased risk for
developing DM2, others, such as Crohn’s disease, inflammatory
arthritis, and systemic autoimmune disorders (e.g., SLE, sclero-
derma) do not [94]. Clearly, communication between metabolic
and immunological regulators is required for the development of
DM2.
Finally, a better understanding of the underlying mechanisms
behind adipose tissue inflammation holds great promise as a
target for future therapeutic intervention. Current clinical prac-
tice mainly focuses on the reduction of blood glucose levels
in DM2 patients [95], which is a consequence of insulin resis-
tance, whereas obesity-induced VAT inflammation is crucial for
the development of this disease. Several phase II and III clinical
trials have been initiated to inhibit key immunological processes of
VAT inflammation in DM2 patients, such as NF-κB signaling, IL-1β
function, or arachidonic acid metabolism, with promising results
[85]. Thus, targeting of inflammatory processes in VAT of obese
patients appears to be a promising future strategy for prophylaxis
against diabetes development.
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